These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6793694)

  • 1. Effects of L-deprenyl on human growth hormone secretion.
    Koulu M; Lammintausta R
    J Neural Transm; 1981; 51(3-4):223-31. PubMed ID: 6793694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human growth hormone and dopaminergic drugs, with special reference to deprenyl (selegiline): a summary of studies on volunteers.
    Koulu M; Lammintausta R
    Acta Neurol Scand Suppl; 1983; 95():91-4. PubMed ID: 6428151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
    Hietala J; Koulu M; Scheinin M; Syvälahti E
    Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.
    Baraczka K; Fekete MI; Kanyicska B
    J Neural Transm; 1983; 58(3-4):299-304. PubMed ID: 6420516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of melatonin on L-tryptophan- and apomorphine-stimulated growth hormone secretion in man.
    Koulu M; Lammintausta R
    J Clin Endocrinol Metab; 1979 Jul; 49(1):70-2. PubMed ID: 447817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men.
    Lal S; Martin JB; De la Vega CE; Friesen HG
    Clin Endocrinol (Oxf); 1975 May; 4(3):277-85. PubMed ID: 1149303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase.
    Nuutila J; Kaakkola S; Männistö PT
    J Neural Transm; 1987; 70(3-4):233-40. PubMed ID: 2960778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term administration of (-)deprenyl (selegiline), a compound which facilitates dopaminergic tone in the brain, leaves the sensitivity of dopamine receptors to apomorphine unchanged.
    Timar J; Knoll B; Knoll J
    Arch Int Pharmacodyn Ther; 1986 Dec; 284(2):255-66. PubMed ID: 3103558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of an effect of melatonin on the basal and L-dopa stimulated growth hormone secretion in men.
    Weinberg U; Weitzman ED; Horowitz ZD; Burg AC
    J Neural Transm; 1981; 52(1-2):117-21. PubMed ID: 7288433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of long-term treatment with deprenyl on basal and L-dopa evoked dopamine release in vitro from the corpus striatum of aged rats.
    Dluzen DE; McDermott JL
    J Neural Transm Gen Sect; 1991; 85(2):145-56. PubMed ID: 1930877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral effects of deprenyl in aged rats.
    Drago F; Continella G; Spadaro F; Cavaliere S; Scapagnini U
    Funct Neurol; 1986; 1(2):165-74. PubMed ID: 3111946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of L-tryptophan on apomorphine-induced growth hormone secretion in normal subjects.
    Lal S; Young SN; Cervantes P; Guyda H
    Pharmakopsychiatr Neuropsychopharmakol; 1980 Nov; 13(6):331-5. PubMed ID: 7208604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenergic and dopaminergic control of growth hormone secretion in urethan anesthetized adult male rats.
    Ruch W; Marbach P; Jaton AL; Bucher B; Doepfner W
    Horm Res; 1978; 9(4):208-24. PubMed ID: 669571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of (-) deprenyl (selegiline) on different behavioral changes induced by dopamine agonists in the rat.
    Timar J; Knoll B; Knoll J
    Pol J Pharmacol Pharm; 1988; 40(6):659-66. PubMed ID: 2908366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influences of catecholamines on growth hormone release in female goldfish, Carassius auratus.
    Chang JP; Marchant TA; Cook AF; Nahorniak CS; Peter RE
    Neuroendocrinology; 1985 Jun; 40(6):463-70. PubMed ID: 3925362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of oral administration of L-dopa on the plasma levels of growth hormone-releasing hormone (GHRH) in normal subjects and patients with various endocrine and metabolic diseases].
    Mitsuhashi S; Yamasaki R; Miyazaki S; Saito H; Saito S
    Nihon Naibunpi Gakkai Zasshi; 1987 Aug; 63(8):934-46. PubMed ID: 3123283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effect of cimetidine on L-dopa-stimulated growth hormone release in normal man.
    Zanoboni A; Galmozzi G; Marinoni S; Zanoboni-Muciaccia W
    Clin Endocrinol (Oxf); 1984 Nov; 21(5):535-40. PubMed ID: 6499233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacology of (-)deprenyl.
    Knoll J
    J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of inhibition by TRH of L-Dopa stimulated GH secretion in patients with alcoholic cirrhosis of the liver.
    Zanoboni A; Zecca L; Zanoboni-Muciaccia W
    Clin Endocrinol (Oxf); 1983 Mar; 18(3):233-9. PubMed ID: 6407788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deprenyl (selegiline): the history of its development and pharmacological action.
    Knoll J
    Acta Neurol Scand Suppl; 1983; 95():57-80. PubMed ID: 6428148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.